Johnson & Johnson: Tracking Well Above The Industry
Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...
FiercePharma5d
J&J angles Darzalex for first move into early-stage myeloma with trial win, FDA filing
J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...
pharmaphorum3d
J&J bids to add smouldering myeloma to Darzalex label
The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...
Cure Today2d
FDA Receives Application Seeking Approval of Darzalex Faspro in Smoldering Myeloma
If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.
Pharmabiz3d
Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma
Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma: Raritan, New Jersey Monday, November ...
Johnson & Johnson Seeks Approval Of Darzalex Faspro In US, Darzalex In EU For Myeloma Treatment
(RTTNews) - Johnson & Johnson (JNJ), Friday announced the submission of regulatory applications for Darzalex Faspro to the U.S. Food and Drug Administration, and Darzalex to the European Medicines ...
Morningstar7d
Genmab Earnings: Robust Demand for Darzalex Drives Sales as Pipeline Advances; Shares Undervalued
Strong royalty revenue from Darzalex (in partnership with wide-moat Johnson & Johnson) is continuing to drive sales. Darzalex remains entrenched in the standard of care for multiple myeloma.
Halozyme: Looking For More Growth Following Record Q3 Earnings
Halozyme's Q3 earnings exceeded expectations, with a $1.27 EPS and 34% YoY revenue growth, driven by ENHANZE tech and strong ...